PSA-based vaccines for the treatment of prostate cancer
- PMID: 16608420
- DOI: 10.1586/14760584.5.2.199
PSA-based vaccines for the treatment of prostate cancer
Abstract
Prostate cancer is the second leading cause of cancer-related death among men in the USA. Vaccine strategies represent a novel therapeutic approach. One potential target for a prostate cancer vaccine is prostate-specific antigen, owing to its restricted expression in prostate cancer and normal prostatic epithelial cells. A number of prostate-specific antigen-specific epitopes have been identified that can activate cytotoxic T lymphocytes and, in turn, result in the killing of tumor targets by the peptide-specific cytotoxic T lymphocytes. Strategies employed in clinical trials consist of dendritic cell vaccines, recombinant protein and recombinant DNA vaccines, as well as viral vector delivery of vaccines. New approaches incorporating a combination of a vaccine with traditional treatments for prostate cancer are also being investigated.
Similar articles
-
Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.Expert Rev Vaccines. 2003 Aug;2(4):483-93. doi: 10.1586/14760584.2.4.483. Expert Rev Vaccines. 2003. PMID: 14711334 Review.
-
Advances in specific immunotherapy for prostate cancer.Eur Urol. 2008 Apr;53(4):694-708. doi: 10.1016/j.eururo.2007.11.043. Epub 2007 Nov 26. Eur Urol. 2008. PMID: 18061335 Review.
-
Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.Prostate. 2009 Jun 15;69(9):938-48. doi: 10.1002/pros.20942. Prostate. 2009. PMID: 19267351
-
CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.Adv Drug Deliv Rev. 2009 Mar 28;61(3):268-74. doi: 10.1016/j.addr.2008.12.005. Epub 2009 Jan 7. Adv Drug Deliv Rev. 2009. PMID: 19166887 Review.
-
Therapeutic vaccines for prostate cancer: a review of clinical data.Curr Opin Investig Drugs. 2005 Jun;6(6):592-6. Curr Opin Investig Drugs. 2005. PMID: 15988910 Review.
Cited by
-
Functional roles of human kallikrein-related peptidases.J Biol Chem. 2009 Nov 27;284(48):32989-94. doi: 10.1074/jbc.R109.027946. Epub 2009 Oct 9. J Biol Chem. 2009. PMID: 19819870 Free PMC article. Review.
-
Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design.Expert Opin Biol Ther. 2010 Jan;10(1):19-28. doi: 10.1517/14712590903321421. Expert Opin Biol Ther. 2010. PMID: 19857185 Free PMC article.
-
Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus.Cancer Immunol Immunother. 2007 Oct;56(10):1615-24. doi: 10.1007/s00262-007-0307-2. Epub 2007 Mar 14. Cancer Immunol Immunother. 2007. PMID: 17356843 Free PMC article.
-
Trial Watch: Toll-like receptor agonists in cancer immunotherapy.Oncoimmunology. 2018 Oct 11;7(12):e1526250. doi: 10.1080/2162402X.2018.1526250. eCollection 2018. Oncoimmunology. 2018. PMID: 30524908 Free PMC article. Review.
-
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.Immunotherapy. 2011 Jan;3(1):27-31. doi: 10.2217/imt.10.77. Immunotherapy. 2011. PMID: 21174555 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
